Zirabev is named as an intervention in 2 current clinical trials in our USA, France, Spain, Italy, Netherlands and Switzerland registers. None are recruiting at the moment. All registered phases are Phase 2. The sponsor with the most trials is AstraZeneca (1). The most-studied condition is Hepatocellular Carcinoma (HCC).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
NCT05601973 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
|
Phase 2 | Active, closed | ETOP IBCSG Partners Foundation | France, Spain, Italy, Netherlands, Switzerland |
|
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
NCT06040099 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)
|
Phase 2 | Active, closed | AstraZeneca | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 1 |
| ETOP IBCSG Partners Foundation | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 0 |
| Clinical trials in France | 1 | 0 |
| Clinical trials in Spain | 1 | 0 |
| Clinical trials in Italy | 1 | 0 |
| Clinical trials in Netherlands | 1 | 0 |
| Clinical trials in Switzerland | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA, France, Spain, Italy, Netherlands and Switzerland registers name Zirabev as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
AstraZeneca (1) and ETOP IBCSG Partners Foundation (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zirabev works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Zirabev works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zirabev (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.